TuHURA draws two more tranches on Parkview credit line, each for $650,000
TuHURA Biosciences tapped its revolving credit facility with Parkview Holdings One on both September 14 and September 21, 2026, pulling $650,000 each time.
SEC filing (2)
Latest
6 stories
Thursday, September 24
Thursday, September 17
TuHURA Biosciences adopts inducement equity plan, adds detail in amended filing
The board reserved 5,000,000 shares for new-hire equity awards, and a follow-up filing clarifies vesting, pricing and disclosure terms.
SEC filing (2)
Friday, September 4
TuHURA Biosciences draws $1.5 million more from Parkview credit line
The Nasdaq-listed company borrowed an additional $1.5 million under its existing revolving credit facility on September 2, 2026.
SEC filing
Friday, August 21
TuHURA draws two more tranches on $50 million Parkview credit line
TuHURA Biosciences borrowed $650,000 on August 7, 2026 and another $650,000 on August 20, 2026 under its revolving credit facility with Parkview Holdings One LLC.
SEC filing (3)
Friday, August 14
TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programs
TuHURA said it filed an IND for its VISTA-inhibiting antibody TBS-2025 and expects to start a Phase 1b/2 AML trial in the second half of 2026, while citing a $50 million credit facility for its cash runway.
SEC filing
Wednesday, July 29
TuHURA Biosciences draws $1.5 million more under Parkview credit facility
The July 28, 2026 draw comes under a revolving loan agreement with Parkview Holdings One LLC that can provide up to $50 million.
SEC filing